Rapamycin alleviates hepatocellular carcinoma progressing in transgenic mice

doi:10.16352/j.issn.1001-6325.2023.08.1241

Abstract

Abstract: Objective Exploring the influence of rapamycin on the progressing of hepatocellular carcinoma(HCC) in H-ras 12V transgenic mice. Methods The expression level of miRNA in liver tissue and peritumor tissue of transgenic mice was detected by high-throughput sequencing of miRNAs. Treatment of transgenic mice with rapamycin and the changes of tumor morphology were detected. The miR-183 expression levels were detected by RT-qPCR. The protein expression levels of mTOR, ERK and PDCD4, the downstream target gene of miR-183, were detected by Western blot. Results Compared with the peritumor tissue, the miR-183 expression in hepatocellular carcinoma tissue was increased significantly (P＜0.01). The protein expression levels of PDCD4 were decreased significantly(P＜0.05). Compared with the control group, after intervention with rapamycin, the counting of liver tumors decreased significantly(P＜0.05). The liver co-efficient decreased significantly(P＜0.05). The ERK phosphorylation increased significantly (P＜0.05). The miR-183 expression was decreased significantly (P＜0.05). The protein level of PDCD4 increased significantly (P＜0.05). Conclusions Rapamycin can alleviate hepatocellular carcinoma progression in H-ras 12V transgenic mice.

Key words: hepatocellular carcinoma, rapamycin, miR-183, PDCD4

CLC Number:

R735.7

LIN Yingxue, CUI Haipeng, WANG Aiguo, YAO Yinhui, ZHAO Juan. Rapamycin alleviates hepatocellular carcinoma progressing in transgenic mice[J]. Basic & Clinical Medicine, 2023, 43(8): 1241-1246.

References 15

[1]	Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021,149:1-61.
[2]	Zhang J, Li H, Dong J, et al. Omics-based identification of shared and gender disparity routes in Hras12V-induced hepatocarcinogenesis: an important role for Dlk1-Dio3 genomic imprinting region[J]. Front Genet, 2021, 12: 620594. doi: 10.3389/fgene.2021.620594.
[3]	Wang AG, Moon HB, Lee MR, et al. Gender-dependent hepatic alterations in H-ras 12V transgenic mice[J]. Hepatol, 2005, 43: 836-844.
[4]	Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation[J]. J Transplant, 2009: 701464. doi: 10.1155/2009/701464.
[5]	Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice[J]. Nature, 2009, 460: 392-395.
[6]	Malagelada C, Jin ZH, Jackson-Lewis V, et al. Rapamy-cin protects against neuron death in in vitro and in vivo models of Parkinson's disease[J]. J Neurosci, 2010, 30: 1166-1175.
[7]	Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy[J]. J Hematol Oncol, 2019, 12:71. doi: 10.1186/s13045-019-0754-1.
[8]	Sun L, Yan Y, Lv H, et al. Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth[J]. Cell Chem Biol, 2022, 29: 373-385.
[9]	Chappell WH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health[J]. Oncotarget, 2011, 2:135-164.
[10]	Albert L, Karsy M, Murali R, et al. Inhibition of mTOR activates the MAPK pathway in glioblastoma[J]. Cancer Genom Proteom, 2009, 6: 255-261.
[11]	马家玲, 高艳平. miR-183靶向Bnip3l对缺氧/复氧的小鼠海马神经元细胞线粒体自噬的影响[J]. 基础医学与临床, 2021, 41: 698-703.
[12]	Zhu W, Liu X, He J, et al. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study[J]. BMC Cancer, 2011, 11: 393. doi:10.1186/1471-2407-11-393.
[13]	Stephan C, Jung M, Rabenhorst S, et al. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue[J]. Clin Chem Lab Med, 2015, 53: 1109-1118.
[14]	Li J, Fu H, Xu C, et al. MiR-183 inhibits TGF-β1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells[J]. BMC Cancer, 2010, 10: 354-363.
[15]	Niu Y, Liu F, Wang X, et al. miR-183-5p promotes HCC migration/invasion via increasing aerobic glycolysis [J]. Onco Targets Ther, 2021, 14: 3649-3658.